[144] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for STOK insider sale. The notice reports a proposed sale of 10,844 common shares with an aggregate market value of $214,277.44 to be executed through Morgan Stanley Smith Barney on NASDAQ on 09/02/2025. The filing identifies the shares as acquired via Restricted Stock Units (03/15/2025), Performance Stock Units (12/31/2024), and the Employee Stock Purchase Plan (06/30/2020), with respective amounts of 6,876, 1,483, and 2,485 shares.

The filing also lists recent dispositions by the same person, including sales on 08/18/2025 (2,805 shares), 08/01/2025 (4,504 shares), 07/01/2025 (4,503 shares), and 06/03/2025 (6,471 shares), several executed under a 10b5-1 plan. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.

Positive

• Transparent disclosure of proposed sale details: number of shares, aggregate market value, broker and planned trade date
• Use of 10b5-1 trading plans for several prior sales, indicating prearranged dispositions and compliance with insider trading controls
• Breakout of acquisition types and dates (RSUs, PSUs, ESPP) provides clear provenance of the sold shares

Negative

• Insider selling activity including multiple recent sales (6/03/2025, 7/01/2025, 8/01/2025, 8/18/2025) which may be interpreted negatively by some market participants
• Proposed sale represents a meaningful single-day transaction (10,844 shares, $214,277.44) that could exert short-term selling pressure depending on liquidity

Insights

Financial Analyst

TL;DR: Routine insider liquidity using Rule 144 and 10b5-1; not an earnings or capital-structure event.

The filing documents a scheduled sale of 10,844 common shares (aggregate value $214,277.44) executed through Morgan Stanley Smith Barney, with the underlying holdings coming from recent RSUs, PSUs and an ESPP. Multiple prior sales in June–August 2025 are disclosed, some under a 10b5-1 plan, indicating pre-planned disposition rather than opportunistic trading. This is a disclosure of insider selling activity and does not itself change the company's financials or capital structure. For investors, the relevance is informational: monitoring aggregate insider selling versus holdings over time is prudent, but the filing alone is neutral absent other material developments.

Corporate Governance Expert

TL;DR: Proper procedural disclosure of insider sales; 10b5-1 usage implies pre-approved trading instructions.

The notice properly identifies the broker, exchange (NASDAQ), acquisition types and dates, and contains the signer’s attestation regarding material nonpublic information. The inclusion of 10b5-1 sales in prior months suggests compliance with adopted trading plans, which reduces the likelihood the trades were based on undisclosed information. From a governance standpoint this is standard practice and represents transparency rather than a governance breach. Materiality remains low unless correlated with other adverse disclosures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10844	214277.44	54797418	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2025	Restricted Stock Units	Issuer			6876	03/15/2025	N/A
Common	12/31/2024	Performance Stock Units	Issuer			1483	12/31/2024	N/A
Common	06/30/2020	Employee Stock Purchase Plan	Issuer			2485	06/30/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BARUCH TICHO 45 Wiggins Ave Bedford MA 01730	Common	08/18/2025	2805	51157.59
10b5-1 Sales for BARUCH TICHO 45 Wiggins Ave Bedford MA 01730	Common	08/01/2025	4504	57724.16
10b5-1 Sales for BARUCH TICHO 45 Wiggins Ave Bedford MA 01730	Common	07/01/2025	4503	52379.35
10b5-1 Sales for BARUCH TICHO 45 Wiggins Ave Bedford MA 01730	Common	06/03/2025	6471	64892.48

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for STOK disclose?

The form discloses a proposed sale of 10,844 common shares valued at $214,277.44, to be executed via Morgan Stanley Smith Barney on NASDAQ on 09/02/2025.

Who acquired the shares being sold and how?

The shares were acquired from the issuer as Restricted Stock Units (03/15/2025, 6,876 shares), Performance Stock Units (12/31/2024, 1,483 shares), and the Employee Stock Purchase Plan (06/30/2020, 2,485 shares).

Were there recent sales by the same person prior to this filing?

Yes. The filing lists sales on 08/18/2025 (2,805 shares), 08/01/2025 (4,504 shares), 07/01/2025 (4,503 shares), and 06/03/2025 (6,471 shares), some executed under a 10b5-1 plan.

Does the Form 144 indicate undisclosed material information?

The signer represents they do not know any material adverse information not publicly disclosed; the filing contains no statement of undisclosed material facts.

Through which broker will the sale be executed?

The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza.